Dallah’s net profit rises 12% to SAR 165 mln in FY15
21/01/2016
Argaam Exclusive
View other reports
Dallah Healthcare Holding Co., which operates hospitals and general clinics, reported a net profit of SAR 165.1 million for fiscal year 2015, a 12.2 percent increase year-on-year (YoY) compared to the same period of 2014 on higher number of patients and the launch of its North Clinics Building during Q1-2015.
Financials (M)
| Item | 2014 | 2015 | Change |
|---|---|---|---|
| Revenues | 858.75 | 985.44 | 14.8 % |
| Gross Income | 358.57 | 407.14 | 13.5 % |
| Operating Income | 145.09 | 160.78 | 10.8 % |
| Net Income | 147.12 | 165.06 | 12.2 % |
| Average Shares | 90.00 | 90.00 | - |
| Earnings Per Share before unusual items (Riyals) | 1.63 | 1.68 | 2.9 % |
| EPS (Riyal) | 1.63 | 1.83 | 12.2 % |
The company reported a net profit of SAR 54.6 million during Q4-2015, an 8 percent YoY rise; and 104 percent increase compared to Q315 on higher number of patients.
Compared With The
Current Quarter Comparison (M)
| Item | Q4 2014 | Q4 2015 | Change |
|---|---|---|---|
| Revenues | 240.08 | 276.50 | 15.2 % |
| Gross Income | 103.54 | 116.81 | 12.8 % |
| Operating Income | 50.24 | 57.01 | 13.5 % |
| Net Income | 50.35 | 54.60 | 8.4 % |
| Average Shares | 90.00 | 90.00 | - |
| Earnings Per Share before unusual items (Riyal) | 0.56 | 0.61 | 8.4 % |
| EPS (Riyal) | 0.56 | 0.61 | 8.4 % |
Financial results (Million)
| Period | Revenues | Change | Gross Income | Change | Operating Income | Change |
|---|---|---|---|---|---|---|
| Q1 2015 | 240.40 | 15.8 % | 102.13 | 16.6 % | 39.67 | (0.1 %) |
| Q2 2015 | 245.23 | 11.7 % | 100.89 | 7.6 % | 35.71 | 6.7 % |
| Q3 2015 | 223.93 | 16.2 % | 87.92 | 16.7 % | 26.37 | 21.7 % |
| Q4 2015 | 276.50 | 15.2 % | 116.81 | 12.8 % | 57.01 | 13.5 % |
| 2015 | 985.44 | 14.8 % | 407.14 | 13.5 % | 160.78 | 10.8 % |
Profit Performance (Million)
| Period | Net Income | Change | EPS(Riyal) | Extraordinary Income/Expense | Net Profit Before Unusual Items | EPS(Riyal) |
|---|---|---|---|---|---|---|
| Q1 2015 | 47.82 | 18.1 % | 0.53 | 13.75 | 34.07 | 0.38 |
| Q2 2015 | 35.86 | 4.4 % | 0.40 | - | 35.86 | 0.40 |
| Q3 2015 | 26.78 | 22.1 % | 0.30 | - | 26.78 | 0.30 |
| Q4 2015 | 54.60 | 8.4 % | 0.61 | - | 54.60 | 0.61 |
| 2015 | 165.06 | 12.2 % | 1.83 | 13.75 | 151.31 | 1.68 |
Profitability
| Period | Gross Margin | OIBDA Margin | Net Margin Before Unusual Items |
|---|---|---|---|
| Q1 2014 | 42.75 % | 23.14 % | 17.85 % |
| Q2 2014 | 42.69 % | 22.94 % | 18.48 % |
| Q3 2014 | 42.42 % | 22.43 % | 17.92 % |
| Q4 2014 | 41.90 % | 22.11 % | 17.11 % |
| 2014 | 41.76 % | 22.14 % | 17.13 % |
| Q1 2015 | 41.98 % | 21.38 % | 15.76 % |
| Q2 2015 | 41.58 % | 21.72 % | 15.48 % |
| Q3 2015 | 41.54 % | 21.77 % | 15.49 % |
| Q4 2015 | 41.35 % | 21.81 % | 15.34 % |
| 2015 | 41.32 % | 22.03 % | 15.35 % |
Compared With The
Per Share Data (Riyal)
| Period | Shares Outstanding (M) | EPS (Riyal) | Earnings Per Share before unusual items (Riyal) | Book Value (BV) |
|---|---|---|---|---|
| Q1 2015 | 90.00 | 1.72 | 1.56 | 14.74 |
| Q2 2015 | 90.00 | 1.73 | 1.58 | 14.63 |
| Q3 2015 | 90.00 | 1.79 | 1.63 | 14.86 |
| Q4 2015 | 90.00 | 1.83 | 1.68 | 15.48 |
Multiple Ratios (End of Period Price)
| Period | P/E | Adjusted P/E | Price/book |
|---|---|---|---|
| Q1 2015 | 41.75 | 45.83 | 4.86 |
| Q2 2015 | 47.66 | 52.27 | 5.65 |
| Q3 2015 | 33.58 | 36.71 | 4.04 |
| Q4 2015 | 28.34 | 30.92 | 3.36 |
Business Segments (Million)
Q4 2015
| Period | Medical Services | Medicine and Pharmaceutical Products |
|---|---|---|
| Q1 2015 | 224.02 | 16.38 |
| Q2 2015 | 228.38 | 16.85 |
| Q3 2015 | 215.41 | 8.52 |
| Q4 2015 | 257.40 | 18.49 |
Analysts Estimates (Million)
| Item | Profit (Expected) | Profit (Actual) | Change |
|---|---|---|---|
| Average | 54.68 | 54.60 | (0.2 %) |
Estimates vs Actual (Million)
| Item | Profit (Expected) | Profit (Actual) | Change |
|---|---|---|---|
| SFC | 57.00 | 54.60 | (4.4) % |
| OSOOL AND BAKHEET | 51.90 | 54.60 | 4.9 % |
| AlJazira Capital | 50.60 | 54.60 | 7.3 % |
| Value Capital | 50.50 | 54.60 | 7.5 % |
| Albilad Capital | 47.00 | 54.60 | 13.9 % |
| Alistithmar Capital | 71.10 | 54.60 | (30.2) % |
| Current | |
| Market Cap (M Riyal) | 13,153.98 |
| Enterprise Value (EV) (M) | 16,152.11 |
| Shares Outstanding ((M)) | 101.58 |
| EPS ( Riyal) (TTM) | 5.00 |
| Book Value (BV) ( Riyal) | 39.98 |
| Par Value ( Riyal) | 10.00 |
| Recurring P/E | 28.84 |
| P/E (TTM) | 25.92 |
| Price/book | 3.24 |
| Return on Average Assets (%) (TTM) | 6.8 |
| Return on Average Equity (%) (TTM) | 13.7 |
| EV/adj EBITDA | 24.32 |
| EV/Revenues | 5.00 |
Share Price
Dallah Healthcare Co. (DALLAH HEALTH)
Follow us on
Comments {{getCommentCount()}}
Be the first to comment
رد{{comment.DisplayName}} على {{getCommenterName(comment.ParentThreadID)}}
{{comment.DisplayName}}
{{comment.ElapsedTime}}